IBI sees 35 upside in Teva share price
IBI sees 35% upside in Teva share price
06:37 EST 17 Dec 2018 |
Globes
IBI analyst Steven Tepper regards the health industry as a long-term investment opportunity.
Original Article: IBI sees 35% upside in Teva share price
More From BioPortfolio on "IBI sees 35% upside in Teva share price"